Appropriate management of cutaneous adverse events maximizes compliance with sorafenib treatment: A single-center experience

Future Oncology

Volumn 8, Issue 5, 2012, Pages 609-615

  Scandurra, Giuseppa ^a   Aiello, Rosa Anna ^a   Alì, Marco ^a   Taibi, Eleonora ^a   Sanò, Maria Vita ^a   Todaro, Francesco Maurizio ^a   La Rocca, Rosaria ^a   Licciardello, Paolo ^a   Caruso, Michele ^a  

^a UF Oncologia Medica   (Italy)

Author keywords

adverse events; guidelines; hand foot skin reaction; multitargeted therapy; prevention; sorafenib; TKI

Indexed keywords

EMOLLIENT AGENT; GLYCOLIC ACID; SALICYLIC ACID; SORAFENIB;

ADULT; AGED; ARTICLE; BLISTER; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; DERMATITIS; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; HAND FOOT AND MOUTH DISEASE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INCIDENCE; INFECTION RISK; ITALY; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; RISK REDUCTION; SHOE; SKIN ABRASION; SKIN BLEEDING; SKIN DISCOMFORT; SKIN EDEMA; SKIN INFECTION; SKIN PAIN; SKIN TOXICITY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; LIVER NEOPLASMS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PYRIDINES; SKIN DISEASES;

EID: 84861755052     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.35     Document Type: Article

References (19)

1. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356(2), 125-134 (2007). (Pubitemid 46089673)
2. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378-390 (2008).
3. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10(1), 25-34 (2009).
4. Strumberg D, Clark JW, Awada A et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: A review of four Phase I trials in patients with advanced refractory solid tumors. Oncologist 12(4), 426-437 (2007). (Pubitemid 46698720)
5. Porta C, Paglino C, Imarisio I, Bonomi L. Uncovering Pandora's vase: The growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin. Exp. Med. 7(4), 127-134 (2007).
6. Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24(26), 4293-4300 (2006). (Pubitemid 46630787)
7. Di Lorenzo G, Porta C, Bellmunt J et al. Toxicities of targeted therapy and their management in kidney cancer. Eur. Urol. 59(4), 526-540 (2011).
8. Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors - A review on pharmacology, metabolism and side effects. Curr. Drug Metab. 10(5), 470-481 (2009).
9. Kirkali Z. Adverse events from targeted therapies in advanced renal cell carcinoma: The impact on long-Term use. BJU Int. 107(11), 1722-1732 (2011).
10. Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24(16), 2505-2512 (2006). (Pubitemid 46630627)
11. Beck J, Procopio G, Bajetta E et al. Final results of the European advanced renal cell carcinoma sorafenib (EU ARCCS) expanded-Access study: A large open-label study in diverse community settings. Ann. Oncol. 22(8), 1812-1823 (2011).
12. Chu D, Lacouture ME, Fillos T, Wu S. Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-Analysis. Acta Oncol. 47(2), 176-186 (2008).
13. Monti M, Motta S. Clinical management of cutaneous toxicity of anti-EGFR agents. Int. J. Biol. Markers 22(1 Suppl. 4), S53-S61 (2007). (Pubitemid 46730023)
14. Lacouture ME, Wu S, Robert C et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 13(9), 1001-1011 (2008).
15. Bellmunt J, Eisen T, Fishman M, Quinn D. Experience with sorafenib and adverse event management. Crit. Rev. Oncol. Hematol. 78(1), 24-32 (2011).
16. Bracarda S, Caserta C, Sordini L, Rossi M, Hamzay A, Crinò L. Protein kinase inhibitors in the treatment of renal cell carcinoma: Sorafenib. Ann. Oncol. 18(Suppl. 6), vi22-vi25 (2007).
17. Iavarone M, Cabibbo G, Piscaglia F et al. Field practice study of sorafenib therapy for hepatocellualr carcinoma: A prospective multicenter study in Italy. Hepatology 54(6), 2055-2063 (2011).
18. Cabibbo G, Palmeri L, Palmeri S, Craxì A. Should cirrhosis change our attitude towards treating non-hepatic cancer? Liver Int. 32(1), 21-27 (2012).
19. Bracarda S, Ruggeri EM, Monti M et al. Early detection, prevention and management of cutaneous adverse events due to sorafenib: Recommendations from the sorafenib working group. Crit. Rev. Oncol. Hematol. doi:10.1016/j. critrevonc.2011.08.005 (2011) (Epub ahead of print).